GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CORBUS PHARMACEUTICALS HOLDINGS INC

Financial Performance:

• No specific financial metrics (revenue, earnings, cash flow, debt) provided; the company is a small pre-revenue drug development entity with approximately 40 employees based in Boston.
• Financial implications of the partnership with Chinese firm CSPC for the oncology asset (Nectin-4 ADC) are not disclosed in this session.

Guidance and Future Outlook:

• Oncology: Aim to file for accelerated approval in the second-line setting by capitalizing on a "frictionless" development program with a track record of on-time milestones; potential pivot to first-line combination with Pembrolizumab if exploratory data matures.
• Obesity: Plans to present full Phase 1b data at a scientific conference later in the week; no explicit regulatory filing dates or commercial launch timelines provided, though data suggests potential for oral GLP-1-level efficacy.
• Long-term: Goal to validate the "brain-excluded" CB1 inverse agonist mechanism as a viable alternative to GLP-1s, potentially serving as a monotherapy for intolerant patients or a combination partner to enhance efficacy.

Business Segments and Product Lines:

• Oncology (CBP-701): Nectin-4 targeting Antibody-Drug Conjugate (ADC) armed with MMAE; partnership with CSPC. Currently in Phase 3 (TEMPO-1) for second-line oropharyngeal squamous cell carcinoma (HPV-positive subset); Phase 1 data shows ~43% objective response rate (ORR) with minimal peripheral neuropathy and skin toxicity. Exploring cervical cancer (Phase 1 data maturing) and first-line combination with Pembrolizumab (data expected Q1 next year).
• Obesity (CRB-913): Once-daily oral small molecule; CB1 inverse agonist engineered for extreme brain exclusion (brain-to-plasma ratio ~1/50th of first-gen drugs). Completed 4-month, double-blind, placebo-controlled Phase 1b with 250 patients (non-diabetic obese).
• Key Differentiators: CRB-913 achieved 5% placebo-adjusted weight loss in 3 months (comparable to oral GLP-1s) with a safety profile mimicking GLP-1s (low psychiatric events, reduced GI side effects compared to older CB1 agonists).

Market and Competitive Landscape:

• Oncology: Second-line head and neck cancer market is an acute unmet need; current options (e.g., EGFR bispecifics like KarXT, Vitraera, or GenMab) show modest efficacy in HPV-positive patients (ORR ~13-29%) or exclude this subset entirely. GenMab's recent frontline data is viewed as disruptive for front-line competitors but less so for second-line opportunities where CBP-701 targets.
• Obesity: CB1 mechanism was historically abandoned due to psychiatric risks (e.g., Rimonabant); Corbus and Novo Nordisk (Mounirolbam) are reviving the class. CRB-913 competes directly with oral and injectable GLP-1s (e.g., Orforglipron, Wegovy) by offering orthogonal mechanism with potentially better GI tolerability and no brain-related psychiatric risks.

Risks and Challenges:

• Clinical Development: Risk that first-line exploratory data (combination with Pembrolizumab) may not meet expectations, potentially limiting market size.
• Safety: While early data suggests psychiatric risks are transient and non-cumulative for CRB-913, long-term exposure risks remain a critical regulatory and commercial hurdle for the CB1 class.
• Competition: The "frontline" head and neck market is becoming crowded (e.g., GenMab), though the second-line space for HPV-positive patients remains less contested.

Management Commentary and Tone:

• CEO Yuval Cohen expressed high confidence in the "brain-excluded" engineering strategy for CRB-913, framing it as a "comeback story" where exclusion from the brain enhances both efficacy and safety.
• Tone was optimistic regarding the oncology pipeline's stability and the unique opportunity to address overlooked HPV-positive patients in head and neck cancer.
• Management emphasized the "two-pole" strategy, contrasting the late-stage ADC with the early-stage oral obesity drug to diversify the portfolio.

Analyst Questions and Answers:

• Q: Comparison to GenMab's recent GenMab frontline data? A: Data is highly disruptive for frontline competitors but minimally impacts Corbus's second-line focus; noted that EGFR bispecifics generally underperform in HPV-positive patients compared to the Nectin-4 target profile.
• Q: Expectations for the first-line combination data next year? A: Targeted to be a medical conference presentation with ~1-2 dozen patients, focusing primarily on response rates (ORR) rather than durability.
• Q: Confidence on long-term psychiatric safety for CRB-913? A: Anxiety/depression risks appear similar to GLP-1s (mild, early, transient, non-dose dependent); no evidence of cumulative risk with longer exposure.
• Q: Why is efficacy higher than first-gen CB1 drugs despite brain exclusion? A: Theory that weight loss is driven by peripheral action; excluding the brain prevents side effects while flooding peripheral receptors enhances potency.

Other Key Points:

• The CRB-913 study design (250 patients, 4 months) was directly comparable to Novo Nordisk's Monlunabam study, allowing for head-to-head efficacy benchmarking.
• Management highlighted that ~50% of second-line head and neck patients currently receive no treatment due to modest efficacy of existing options, representing a significant market opportunity.
• Potential for CRB-913 to be combined with oral GLP-1s to enhance efficacy without worsening GI side effects was discussed as a future strategic avenue.